Cardiac Arrhythmias: New Therapeutic Drugs and Devices

Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984

  • Joel Morganroth
  • E. Neil Moore

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 47)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Basic considerations

    1. Front Matter
      Pages 1-1
    2. Brian F. Hoffman
      Pages 12-21
    3. Back Matter
      Pages 41-47
  3. Status of Specific Antiarrhythmic Agents

  4. Special Considerations and FDA Standards

  5. New Antiarrhythmic Devices

    1. Front Matter
      Pages 235-235
    2. John D. Fisher
      Pages 247-254
    3. Eric N. Prystowsky, William M. Miles, James J. Heger, Douglas P. Zipes
      Pages 255-261
    4. Roger A. Winkle, Debra S. Echt, R. Hardwin Mead, Vincent Gaudiani, Edward B. Stinson, Paula Schmidt
      Pages 262-272
    5. Back Matter
      Pages 279-290
  6. Evaluation of Atrial Arrhythmias

    1. Front Matter
      Pages 291-291
    2. John C. Somberg, Vilma Torres
      Pages 315-334
    3. Back Matter
      Pages 335-343
  7. Back Matter
    Pages 345-356

About this book


In summary, there are many animal models that are useful in selecting new antiarrhythmic drugs. The selection of which model is most idea depends upon precisely what question is being asked. The large number of experimental models used to evaluate antiarrhythmic compounds points out the inability of anyone model to define the probability of antiarrhythmic efficacy in man. It has therefore become standard practice to utilize a batter of animal models for the evaluation of new antiarrhythmic agents. Each model has its own advantages and disadvantages and it is necessary to understand each model fully in oder to evaluate experimental findings and apply them to clinical settings. We believe that the availability of the chronic myocardial infarction ventricular tachyarrhythmia model provides 1) an excellent opportunity to more precisely understand arrhythmia mechanisms, 2) to develop new techniques such as signal averaging for evaluating late low level potentials identifying hearts at high risk of sudden death 3) to identify new antifibrillatory drugs versus drugs that are effective primarily against PVC's and ventricular tachycardia 4) to identify new surgical techniques to eliminate VT/VF, and 5) to evaluate new pacing modalities including implantable cardioverters. Although all animal models are wrong, many are very useful in furthering our knowledge directed at decreasing the distressingly high mortality from heart disease. NORMAL HtART TACHYCMDIA HtART , .. '" \ I I I I I I I I I .


arrhythmia drug drugs heart heart disease myocardial infarction research sudden cardiac death

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  1. 1.Likoff Cardiovascular Institute of Hahnemann Medical College and HospitalUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1985
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-9626-3
  • Online ISBN 978-1-4613-2595-6
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology